Replies to post #121602 on Cytodyn Inc (CYDY)

[Badge04]

There is no more difficult patient population to conduct studies on. Period. It’s why new therapies for severe sepsis and similar clinical settings have been lacking. Improving the survival rate on a critically ill patient is a monumental task, and typically the enrollment numbers are massive just to power them correctly. I am eager to see these interim results. I expect the trial will need to continue to its endpoint before the FDA decides the fate of leronlimab for this indication. However, if it shows clinical or statistical significance in this critically ill population, we are sitting on an absolute gold mine.